Literature review and hospital information system data real world clinical outcome analysis of role of parenterally administered shenmai in treatment of shock.
- Author:
Lian-Xin WANG
1
;
Hao TANG
2
;
Yan-Ming XIE
3
Author Information
1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. wanglianxin_tcm@126.com
2. Renmin University of China, Beijing 100872, China.
3. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
- Publication Type:Journal Article
- MeSH:
Drug Combinations;
Drugs, Chinese Herbal;
administration & dosage;
Hospital Information Systems;
statistics & numerical data;
Humans;
Infusions, Parenteral;
Pragmatic Clinical Trials as Topic;
Retrospective Studies;
Shock;
drug therapy
- From:
China Journal of Chinese Materia Medica
2013;38(18):3104-3109
- CountryChina
- Language:Chinese
-
Abstract:
Parenterally administered Shenmai has the functions of benefiting vital energy, nourishing Yin, generating body fluids, and activating the pulse. Modern pharmacological studies have shown that constituents of parenterally administered Shenmai such as ginsenosides and ophiopogonin can improve hypoxia tolerance, immunity, function, and microcirculation of the heart, and free radical scavenging. Therefore, parenterally administered Shenmai is a suitable treatment for shock. Literature review and analysis of HIS data outcomes, are the two methods used to study the type of shock treated, dose and combinations of other medications used with parenterally administered Shenmai. The results of the two methods are consistent in understanding the clinical features of shock therapy with parenterally administered Shenmai which thereby provides information for the design of prospective studies. However, the results of the two methods are limited by the poor quality of the literature and the low level of evidence for clinical evaluation after the registration of Shenmai. Nevertheless, HIS data provides retrospective data although some information is missing. Thus, although the results of the two methods can be used as the foundation to support the clinical evaluation of post-marketing parenterally administered Shenmai, final conclusions can only be drawn based on prospective studies.
